Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Savara Inc. has received a consensus rating of "Moderate Buy" from five brokerages, with an average 12-month target price of $5.60.
• Several analysts have modified their price targets, with HC Wainwright reducing theirs from $6.00 to $2.00 and Guggenheim reaffirming a buy rating with a target of $8.00.
• Insider Richard J. Hawkins purchased 48,225 shares at an average cost of $2.04, significantly increasing his position in the company.

Savara Inc. (NASDAQ:SVRA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $5.60.

Several research firms have commented on SVRA. HC Wainwright cut Savara from a "buy" rating to a "neutral" rating and lowered their price target for the company from $6.00 to $2.00 in a report on Thursday, May 29th. Evercore ISI reduced their price objective on Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research note on Wednesday, May 28th. Wells Fargo & Company reduced their price objective on Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 28th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $8.00 price objective (down from $9.00) on shares of Savara in a research note on Wednesday, May 28th.

Insider Buying and Selling

In related news, Director Richard J. Hawkins purchased 48,225 shares of Savara stock in a transaction that occurred on Friday, June 20th. The shares were purchased at an average cost of $2.04 per share, with a total value of $98,379.00. Following the transaction, the director owned 115,466 shares of the company's stock, valued at approximately $235,550.64. The trade was a 71.72% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 5.33% of the company's stock.

Hedge Funds Weigh In On Savara

Several hedge funds and other institutional investors have recently bought and sold shares of SVRA. JPMorgan Chase & Co. lifted its position in Savara by 1,948.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,423,139 shares of the company's stock worth $4,369,000 after acquiring an additional 1,353,649 shares in the last quarter. Geode Capital Management LLC lifted its position in Savara by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 2,784,037 shares of the company's stock worth $8,549,000 after acquiring an additional 57,187 shares in the last quarter. Wells Fargo & Company MN lifted its position in Savara by 42.9% during the 4th quarter. Wells Fargo & Company MN now owns 59,277 shares of the company's stock worth $182,000 after acquiring an additional 17,786 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Savara in the 4th quarter valued at approximately $798,000. Finally, Barclays PLC raised its position in shares of Savara by 2.5% in the 4th quarter. Barclays PLC now owns 236,705 shares of the company's stock valued at $728,000 after purchasing an additional 5,700 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Stock Up 4.7%

SVRA opened at $2.70 on Thursday. The company has a debt-to-equity ratio of 0.20, a current ratio of 14.91 and a quick ratio of 14.91. The stock has a market capitalization of $466.67 million, a price-to-earnings ratio of -5.62 and a beta of 0.40. The business has a 50-day moving average of $2.37 and a two-hundred day moving average of $2.66. Savara has a 12 month low of $1.89 and a 12 month high of $4.70.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). On average, research analysts expect that Savara will post -0.45 earnings per share for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.